<SEC-DOCUMENT>0000950103-22-015362.txt : 20220907
<SEC-HEADER>0000950103-22-015362.hdr.sgml : 20220907
<ACCEPTANCE-DATETIME>20220907093445
ACCESSION NUMBER:		0000950103-22-015362
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220907
FILED AS OF DATE:		20220907
DATE AS OF CHANGE:		20220907

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADC Therapeutics SA
		CENTRAL INDEX KEY:			0001771910
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39071
		FILM NUMBER:		221230117

	BUSINESS ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
		BUSINESS PHONE:		41 21 653 02 00

	MAIL ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp179982-6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of September 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 15%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File Number: 001-39071</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ADC Therapeutics SA</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Biop&ocirc;le</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Route de la Corniche 3B</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>1066 Epalinges</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Switzerland</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of <BR>
Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 12pt">Form 20-F</FONT></TD>
    <TD STYLE="width: 14%">
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">&#9746;</P></TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 12pt">Form 40-F</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 14%">
</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ADC Therapeutics SA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: September 7, 2022</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Michael Forer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Michael Forer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President &amp; General Counsel</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; width: 15%"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="padding: 2pt; width: 85%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding: 2pt"><FONT STYLE="font-size: 10pt">Press release dated September 6, 2022</P>

<P STYLE="margin: 0pt 0; font: 11pt Arial, Helvetica, Sans-Serif"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0pt 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR><BR>
</P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp179982-ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><IMG SRC="image_002.jpg" ALT="">&nbsp;</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt"><B>ADC
Therapeutics to Participate in Morgan Stanley&rsquo;s 20<SUP>th</SUP> Annual Global Healthcare Conference</B></FONT></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>LAUSANNE,
Switzerland, September 6, 2022</B> &ndash; ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer,
will participate in a fireside chat at Morgan Stanley&rsquo;s 20<SUP>th</SUP> Annual Global Healthcare Conference on Tuesday, September
13<SUP>th</SUP> at 11:45 a.m. ET.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">A
live webcast of the presentation will be available via the Events &amp; Presentations page in the Investors section of ADC Therapeutics&rsquo;
website, ir.adctherapeutics.com. A replay of the webcast will be available
for approximately 30 days.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>About
ADC Therapeutics</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">ADC
Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation,
targeted antibody drug conjugates (ADCs).&nbsp;The Company is advancing its proprietary PBD-based ADC technology to transform the treatment
paradigm for patients with hematologic malignancies and solid tumors.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">ADC
Therapeutics&rsquo; CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or
refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination
with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma
and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs
in ongoing clinical and preclinical development.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">ADC
Therapeutics is based in Lausanne (Biop&ocirc;le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.
For more information, please visit https://adctherapeutics.com/ and follow the Company on&nbsp;Twitter&nbsp;and&nbsp;LinkedIn.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">ZYNLONTA&reg;
is a registered trademark of ADC Therapeutics SA.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Investors</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Eugenia
Litz</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">ADC
Therapeutics</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Eugenia.Litz@adctherapeutics.com</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">+44
7879 627205</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Amanda
Hamilton</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">ADC
Therapeutics</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">amanda.hamilton@adctherapeutics.com</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">+1
917-288-7023</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>USA
Media</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Mary
Ann Ondish<BR>
ADC Therapeutics<BR>
maryann.ondish@adctherapeutics.com</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Tel.:
+1 914-552-4625</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !B *X# 2(  A$! Q$!_\0
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MI;C225D%%%5[Z]@TZT>YN7"1H/Q/L/>DVDKLJ,7)V6Y-)*D,;22NJ(HR68X
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( !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
